AICAR

AICAR (acadesine) is a non-peptide research compound discussed for endurance and fat loss. Some people report easier cardio; others notice little or feel worse, often while using other drugs. Dose claims conflict; measured clinical IV kinetics do not establish timing for community injection products or long-term safety.

An energy-sensing research compound. AICAR usually means acadesine (AICA riboside), a small molecule rather than a peptide. Cells convert it into ZMP, a different molecule that can activate the energy-sensing enzyme AMPK and alter fuel use. Dixon et al. — acadesine disposition and metabolism (Official context · Accessed 2026-09-30) · Narkar et al. — AMPK and PPARdelta agonists are exercise mimetics (Animal context · Accessed 2026-09-30)

“Exercise mimetic” describes the idea. Bodybuilding discussion borrows this phrase from mouse research, hoping for easier cardio or fat loss. It does not mean every benefit of training is reproduced. AICAR also differs from ALCAR, acetyl-L-carnitine. AICAR Reviewed — Josh Hodnik (Community guide · Accessed 2026-09-30) · AICAR experiences? (Community discussion · Accessed 2026-09-30)

Source context — Dixon et al. — acadesine disposition and metabolism: API abstract reviewed, not full text. PubMed returned empty; Europe PMC article frontend failed.

Source context — Narkar et al. — AMPK and PPARdelta agonists are exercise mimetics: Mouse/cell findings, not human dosing or consumer oral efficacy. Article calls AICAR orally active but reported AICAR endurance administration was i.p.

Source context — AICAR Reviewed — Josh Hodnik: Bodybuilding explainer, not a use log; dated price/scaling and assertion of no human trials are not adopted.

Source context — AICAR experiences?: Anonymous, unverified products and co-use; describes discussion, not effectiveness, incidence or a safe regimen. Positive account has no amount/route; deleted username means continuity follows nesting, not identity verification.

Cardio that feels easier. Two favorable Reddit accounts describe cardio improvement, without objective testing or enough detail to establish who responds. Personal enthusiasm does not establish a predictable performance benefit. AICAR experiences? (Community discussion · Accessed 2026-09-30) · Aicar — pills, vials and cardio replies (Community discussion · Accessed 2026-09-30)

Early fat-loss optimism did not become a clear result. Odin's Son's early local-fat impression became little overall difference. He credited Helios for the speedy, hot feeling; GW501516, RIPS and hormonal drugs also accompanied AICAR. AICAR dosing protocol — Odin's Son's evolving stack account (Personal report · Accessed 2026-09-30)

Oral tolerance can differ from injection experience. The pills-and-vials commenter used half a pill because a full pill caused a toilet rush; strength was forgotten. Their positive cardio reply cannot separate oral from injection effects. Aicar — pills, vials and cardio replies (Community discussion · Accessed 2026-09-30)

A negative stack story was contested. One MuscleChemistry narrator alleged lower stamina, slower recovery, low HDL cholesterol and palpitations in a group account. Replies challenged its credibility. Repeated quotations are not corroboration, and GW co-use prevents AICAR-specific attribution. ACTH 1-39 & AICAR — contested AICAR/GW account (Community discussion · Accessed 2026-09-30)

Source context — AICAR experiences?: Anonymous, unverified products and co-use; describes discussion, not effectiveness, incidence or a safe regimen. Positive account has no amount/route; deleted username means continuity follows nesting, not identity verification.

Source context — Aicar — pills, vials and cardio replies: Anonymous, unverified products and co-use; describes discussion, not effectiveness, incidence or a safe regimen. Pill strength forgotten; 10 mg frequency/route not fully resolved.

Source context — AICAR dosing protocol — Odin's Son's evolving stack account: Anonymous, unverified products and co-use; describes discussion, not effectiveness, incidence or a safe regimen. Replies misidentify AICAR as a peptide and scale animal doses; not adopted.

Source context — ACTH 1-39 & AICAR — contested AICAR/GW account: Anonymous, unverified products and co-use; describes discussion, not effectiveness, incidence or a safe regimen. One narrator's alleged group experience, not four independent logs; sequence is awkward and total course not reconciled.

Reported injection use: 10 mg daily. Odin's Son reported this daily total in a stack. He considered 20 mg every other day and heard of 100 mg every other day; these were alternatives, not tested effective amounts. AICAR dosing protocol — Odin's Son's evolving stack account (Personal report · Accessed 2026-09-30)

Another account: 10 mg per use. A 2025 commenter described five vial doses/week, then named 10 mg; injection route and course were unstated. Another person's 25 mg/day for two weeks was a website claim discussed as pill dosing. Aicar — pills, vials and cardio replies (Community discussion · Accessed 2026-09-30)

A proposed 50 mg/day is not a completed log. A 2023 poster contemplated four weeks at this daily amount, asking about subcutaneous versus intramuscular use. No outcome was reported. AICAR experiences? (Community discussion · Accessed 2026-09-30)

Charts disagree: 1–5 mg/day versus 50–150 mg/day. PeptiJournal lists 1–5 mg/day subcutaneously; Everything Peptide lists 50–150 mg/day IV or subcutaneously. These commercial/calculator summaries do not establish human effectiveness or an interchangeable range. PeptiJournal — AICAR protocol reference (Community guide · Accessed 2026-09-30) · Everything Peptide — AICAR dosage chart (Community guide · Accessed 2026-09-30)

Older micro-plans: about 100–150 mcg/day. Older bodybuilding summaries mention microgram plans and skepticism about their effects, alongside multi-gram speculation. These unverified claims differ from milligram charts and do not establish an effective amount.

Source context — AICAR dosing protocol — Odin's Son's evolving stack account: Anonymous, unverified products and co-use; describes discussion, not effectiveness, incidence or a safe regimen. Replies misidentify AICAR as a peptide and scale animal doses; not adopted.

Source context — Aicar — pills, vials and cardio replies: Anonymous, unverified products and co-use; describes discussion, not effectiveness, incidence or a safe regimen. Pill strength forgotten; 10 mg frequency/route not fully resolved.

Source context — AICAR experiences?: Anonymous, unverified products and co-use; describes discussion, not effectiveness, incidence or a safe regimen. Positive account has no amount/route; deleted username means continuity follows nesting, not identity verification.

Source context — PeptiJournal — AICAR protocol reference: Commercial calculator/service summary, not measured user response; blends riboside/ribonucleotide naming and offers unsupported safety-margin assurance.

Source context — Everything Peptide — AICAR dosage chart: Commercial promotion and generic peptide template; neither cited rodent study establishes a human IV/SC regimen. Preparation instructions excluded.

One cardio report: within three days. The 2023 contributor noticed improvement within three days of starting. Amount, route and co-use were unstated; this does not establish onset after each administration. AICAR experiences? (Community discussion · Accessed 2026-09-30)

Minutes after a dose: not established. Personal accounts supply no dependable AICAR-only first-effect time. Injection discomfort or stomach upset is not the onset of endurance improvement. Aicar — pills, vials and cardio replies (Community discussion · Accessed 2026-09-30)

No reliable one-dose effect window. The accounts establish neither a duration in hours nor persistence after stopping. Course length and blood half-life cannot supply that answer. AICAR experiences? (Community discussion · Accessed 2026-09-30) · Aicar — pills, vials and cardio replies (Community discussion · Accessed 2026-09-30)

Human IV half-life: about 1.4 hours. Dixon's healthy-men study measured this terminal parent-acadesine half-life after IV use; oral-solution absorption was below 5%. These findings do not establish subcutaneous or intramuscular timing, or pill performance. Dixon et al. — AICA-riboside safety, tolerance and pharmacokinetics (Official context · Accessed 2026-09-30)

A circulated 2–3-hour plasma estimate. Peptide Schedule displays 2.5 hours, estimated from clinical data with low confidence. This aggregator extrapolation is not a measured human subcutaneous half-life. Peptide Schedule — AICAR timing estimate (Community guide · Accessed 2026-09-30)

Community injection half-life remains uncertain. Personal accounts do not measure clearance. Blood levels halving, ZMP remaining inside cells and training feeling different are separate questions. AICAR experiences? (Community discussion · Accessed 2026-09-30) · Aicar — pills, vials and cardio replies (Community discussion · Accessed 2026-09-30)

Source context — AICAR experiences?: Anonymous, unverified products and co-use; describes discussion, not effectiveness, incidence or a safe regimen. Positive account has no amount/route; deleted username means continuity follows nesting, not identity verification.

Source context — Aicar — pills, vials and cardio replies: Anonymous, unverified products and co-use; describes discussion, not effectiveness, incidence or a safe regimen. Pill strength forgotten; 10 mg frequency/route not fully resolved.

Source context — Dixon et al. — AICA-riboside safety, tolerance and pharmacokinetics: Abstract reviewed, not full text; small acute study does not establish community route, chronic safety or performance.

Source context — Peptide Schedule — AICAR timing estimate: Aggregator/calculator claim, no verified human SC measurement. Other page safety and treatment advice not adopted.

Five days on/five off; two on/two off. A nested follow-up to the positive 2023 report favored these breaks after feeling unwell. Its “out of control” metabolism explanation was unmeasured, and these patterns do not establish protection from harm. AICAR experiences? (Community discussion · Accessed 2026-09-30)

A disputed longer stack account. A MuscleChemistry poster described 100 mg per use twice weekly for a month, then three times weekly, then 13 mg/day in eight-on/two-off blocks for 40 days. The account involved AICAR plus GW1516; respondents challenged its credibility. ACTH 1-39 & AICAR — contested AICAR/GW account (Community discussion · Accessed 2026-09-30)

No agreed safe calendar. Short plans and different break patterns appear alongside cost and tolerance concerns. Neither a four-week plan nor repeated breaks establish a standard calendar or safe long-term use. AICAR experiences? (Community discussion · Accessed 2026-09-30)

Source context — AICAR experiences?: Anonymous, unverified products and co-use; describes discussion, not effectiveness, incidence or a safe regimen. Positive account has no amount/route; deleted username means continuity follows nesting, not identity verification.

Source context — ACTH 1-39 & AICAR — contested AICAR/GW account: Anonymous, unverified products and co-use; describes discussion, not effectiveness, incidence or a safe regimen. One narrator's alleged group experience, not four independent logs; sequence is awkward and total course not reconciled.

With GW501516 lore: Exercise-mimetic stack stories — still preclinical-heavy. [community]

A negative stack story was contested. One MuscleChemistry narrator alleged lower stamina, slower recovery, low HDL cholesterol and palpitations in a group account. Replies challenged its credibility. Repeated quotations are not corroboration, and GW co-use prevents AICAR-specific attribution. ACTH 1-39 & AICAR — contested AICAR/GW account (Community discussion · Accessed 2026-09-30)

Race times and milliliters can mislead. An EliteFitness runner's times involved other performance drugs. Half a milliliter every other day lacked concentration; another poster questioned the missing milligrams. Bowel problems/dehydration were initially attributed to GW. Aicar Log Endurance Runner (Personal report · Accessed 2026-09-30)

Early fat-loss optimism did not become a clear result. Odin's Son's early local-fat impression became little overall difference. He credited Helios for the speedy, hot feeling; GW501516, RIPS and hormonal drugs also accompanied AICAR. AICAR dosing protocol — Odin's Son's evolving stack account (Personal report · Accessed 2026-09-30)

Hormonal-stack talk is not AICAR suppression. Bloodwork and post-cycle therapy discussions may concern accompanying hormonal drugs. They do not establish that AICAR suppresses testosterone or needs post-cycle therapy.

Source context — ACTH 1-39 & AICAR — contested AICAR/GW account: Anonymous, unverified products and co-use; describes discussion, not effectiveness, incidence or a safe regimen. One narrator's alleged group experience, not four independent logs; sequence is awkward and total course not reconciled.

Source context — Aicar Log Endurance Runner: Anonymous, unverified products and co-use; describes discussion, not effectiveness, incidence or a safe regimen. Race changes are heavily confounded; initial bowel/dehydration account concerned GW.

Source context — AICAR dosing protocol — Odin's Son's evolving stack account: Anonymous, unverified products and co-use; describes discussion, not effectiveness, incidence or a safe regimen. Replies misidentify AICAR as a peptide and scale animal doses; not adopted.

Uncertain chronic safety and product identity. Long-term human safety, interactions and research-product identity remain uncertain. Older discussion includes redness, itching, lumps or bruising after injections, and oral stomach or mood complaints, without dependable rates.

Prohibited in tested sport at all times. WADA lists AICAR under S4.4.1 metabolic modulators. Forum half-life claims cannot establish an anti-doping clearance interval. WADA Prohibited List — S4 metabolic modulators (Official context · Accessed 2026-09-30)

Serious symptoms need medical care. Chest pain, severe allergic reactions, neurological changes or uncontrolled blood pressure or glucose need medical assessment. A stack log cannot identify the culprit; shorter cycles do not assure safety.

Source context — WADA Prohibited List — S4 metabolic modulators: Sport eligibility rule, not a safety or detection-time assessment.